发病4.5小时内氨甲环酸治疗伴CTA点征的脑出血:系统评价与个体患者荟萃分析
该系统评价与个体患者荟萃分析纳入3项随机试验共162例伴点征的原发性脑出血患者,比较发病4.5小时内氨甲环酸与安慰剂。氨甲环酸组血肿扩大36/74(49%),安慰剂组48/88(55%),校正RR 0.86(95%CI 0.84-0.89,p<0.001);校正中位绝对血肿增长减少1.60 mL(95%CI 0.77-2.43)。功能结局与安全性无差异,结果需进一步验证后方可临床应用。
要点
- 发病4.5小时内氨甲环酸可轻度降低伴CTA点征脑出血患者的血肿扩大。
- 氨甲环酸组血肿扩大49% vs 安慰剂组55%,校正RR 0.86(95%CI 0.84-0.89)。
- 功能结局与安全性无差异,作者认为结果需进一步验证后方可临床应用。
核心结论
- 发病4.5小时内氨甲环酸轻度降低伴CT血管造影点征脑出血患者的血肿扩大。
- 鉴于纳入荟萃分析的各项试验单独结果均为中性,这些结果需进一步验证后方可临床应用。
研究设计与样本
- 系统评价与个体患者荟萃分析,按个体参与者数据系统评价与荟萃分析优先报告条目指南报告。
- 检索PubMed与Embase自建库至2023年5月29日,检索词为((stroke) AND (randomised OR randomized) AND (tranexamic acid) AND (haemorrhage OR hemorrhage))。
- 纳入比较氨甲环酸与安慰剂、伴点征且在规定时间内完成随访影像的原发性脑出血随机试验。
- 共识别197项研究,3项符合条件,提供162例参与者用于主要分析(女性60例、男性102例)。
- 个体患者数据由各研究提供并由协调中心整合,采用随机效应模型合并,主要终点分析使用混合效应修正Poisson回归并校正基线血肿体积。
主要发现
- 氨甲环酸组血肿扩大36/74(49%),安慰剂组48/88(55%),校正风险比0.86(95%CI 0.84-0.89,p<0.001)。
- 校正中位绝对血肿增长氨甲环酸组较安慰剂组减少1.60 mL(95%CI 0.77-2.43)。
- 功能结局与安全性(90天内死亡与主要血栓栓塞事件)未见差异。
关键数值与推荐
- 主要终点为24小时内血肿扩大,定义为较基线相对扩大≥33%或绝对扩大≥6 mL。
- 安全性结局为90天内死亡与主要血栓栓塞事件。
局限性
- 作者指出纳入荟萃分析的各项试验单独结果均为中性,这些结果需进一步验证后方可临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The antifibrinolytic agent tranexamic acid has been tested in intracerebral hemorrhage trials with overall neutral results. Ongoing contrast extravasation on CT angiography (spot sign) can identify individuals with ongoing bleeding who may benefit from anti-fibrinolytic therapy. We aimed to investigate the effect of tranexamic acid on hematoma growth in patients with spot signs treated within 4.5 hours of onset. METHODS: We conducted a systematic review and individual patient meta-analysis, which we report according to the Preferred Reporting Items for Systematic Review and Meta-analyses of Individual Participant Data guidelines. PubMed and Embase were searched from inception to May 29, 2023, using the terms ((stroke) AND (randomised OR randomized) AND (tranexamic acid) AND (haemorrhage OR hemorrhage)). We included randomized trials comparing tranexamic acid with placebo in participants with primary intracerebral hemorrhage who had a spot sign and who had follow-up imaging within the required timeframe. Individual patient data were provided by each study and were integrated by the coordinating center. Data were pooled using a random-effects model. The primary endpoint was hematoma growth within 24 hours, defined as ≥33% relative or ≥6 mL absolute hematoma expansion compared with baseline, analyzed using mixed-effects-modified Poisson regression with robust standard errors, adjusted for baseline hematoma volume. Safety outcomes were mortality and major thromboembolic events within 90 days. RESULTS: Of 197 studies identified, 3 were eligible, contributing 162 participants for the primary analysis (60 female and 102 male). Hematoma growth occurred in 36 of 74 (49%) participants treated with tranexamic acid, compared with 48 of 88 (55%) participants treated with placebo (adjusted risk ratio 0.86, 95% CI 0.84-0.89, p < 0.001). Adjusted median absolute hematoma growth was 1.60 mL (95% CI 0.77-2.43) lower with tranexamic acid vs placebo. No differences in functional outcome or safety were observed. DISCUSSION: Tranexamic acid modestly reduced hematoma growth in patients with CT angiography spot signs treated within 4.5 hours of onset. Given the trials in the meta-analysis were individually neutral, these results require further validation before clinical application.
引用
- Yassi N, Yogendrakumar V, Churilov L, et al. Tranexamic Acid Within 4.5 Hours of Intracerebral Hemorrhage With the CTA Spot Sign: Systematic Review and Individual Patient Meta-analysis. Neurology. 2024. PMID: 39586046. doi:10.1212/WNL.0000000000210104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。